Isabelle Trouilloud
University of Paris
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Isabelle Trouilloud.
Journal of the National Cancer Institute | 2016
David Tougeron; Guillaume Mouillet; Isabelle Trouilloud; Thierry Lecomte; Romain Coriat; Thomas Aparicio; Gaetan Des Guetz; Cedric Lecaille; Pascal Artru; Gaelle Sickersen; Estelle Cauchin; David Sefrioui; Tarek Boussaha; Aurélie Ferru; Tamara Matysiak-Budnik; Christine Silvain; Lucie Karayan-Tapon; Jean-Christophe Pagès; Dewi Vernerey; Franck Bonnetain; Pierre Michel; Julien Taieb; Aziz Zaanan
BACKGROUND Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant chemotherapy while preliminary data suggest chemosensitivity to oxaliplatin. We assessed the efficacy of fluoropyrimidine with and without oxaliplatin in a large cohort of dMMR CC patients. METHODS This retrospective multicenter study included all consecutive patients who underwent curative surgical resection for stage II or III dMMR CC between 2000 and 2011. Prognostic factors were analyzed using Cox models, and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. All statistical tests were two-sided. RESULTS A total of 433 dMMR CC patients were included (56.8% stage II, 43.2% stage III). Mean follow-up was 47.0 months. The patients received surgery alone (n = 263) or surgery plus adjuvant chemotherapy consisting of fluoropyrimidine with (n = 119) or without (n = 51) oxaliplatin. Adjuvant chemotherapy was administered to 16.7% of stage II and 69.0% of stage III CC patients. As compared with surgery alone, adjuvant oxaliplatin-based chemotherapy improved disease-free survival (DFS) in multivariable analysis (HR = 0.35, 95% CI = 0.19 to 0.65, P < .001), contrary to adjuvant fluoropyrimidine alone (HR = 0.73, 95% CI = 0.36 to 1.49, P = .38). In the subgroup analysis, the DFS benefit of oxaliplatin-based chemotherapy was statistically significant in multivariable analysis only in stage III (HR = 0.41, 95% CI = 0.19 to 0.87, P = .02). CONCLUSION This study supports the use of adjuvant chemotherapy with fluoropyrimidine plus oxaliplatin in stage III dMMR CC.
Cancer | 2015
Bertrand Brieau; Laetitia Dahan; Yann De Rycke; Tarek Boussaha; Philippe Vasseur; David Tougeron; Thierry Lecomte; Romain Coriat; Jean-Baptiste Bachet; Pierre Claudez; Aziz Zaanan; Pauline Soibinet; Jérôme Desramé; Anne Thirot-Bidault; Isabelle Trouilloud; Florence Mary; Lysiane Marthey; Julien Taieb; Wulfran Cacheux; Astrid Lièvre
Few data are available on second‐line chemotherapy (CT2) for advanced biliary tract cancer (ABTC). The aim of this multicenter study was to describe the CT2 regimens used, the response rates, and the outcomes of patients treated with various CT2 regimens.
European Journal of Cancer | 2015
David Tougeron; Gaelle Sickersen; Guillaume Mouillet; Aziz Zaanan; Isabelle Trouilloud; Romain Coriat; Thomas Aparicio; G. Des Guetz; Cedric Lecaille; Pascal Artru; Estelle Cauchin; David Sefrioui; Tarek Boussaha; Aurélie Ferru; Tamara Matysiak-Budnik; Christine Silvain; Lucie Karayan-Tapon; Jean-Christophe Pagès; Dewi Vernerey; Franck Bonnetain; Pierre Michel; Julien Taieb; Thierry Lecomte
BACKGROUND A microsatellite instability (MSI) phenotype is found in about 12% of colorectal cancers (CRCs) and is associated with a low recurrence rate after curative surgery. Several studies have identified clinical and pathological factors predictive of recurrence in resected CRC, but not in the MSI subgroup. PATIENTS AND METHODS This multicentre retrospective study included patients with stage I, II or III MSI CRCs. Disease-free survival (DFS) was calculated with the Kaplan-Meier method. Factors associated with DFS were identified in univariate and multivariate Cox analyses. RESULTS We studied 521 patients with MSI CRC. Respectively 11%, 51% and 38% of patients were at stage I, II and III. Mean age was 68.7years and 36% of the patients received adjuvant chemotherapy. Median follow-up was 32.8months. The disease recurrence rates were 6% and 21% in stage II and III patients, respectively. The 3-year DFS rate was 77%. In univariate analysis, age, bowel obstruction, lymph node invasion, stage T4, vascular emboli, lymphatic invasion and perinervous invasion were associated with poorer DFS (P<0.05). Three relevant independent predictors of poor DFS were identified in multivariate analysis, namely bowel obstruction (HR=2.46; 95%CI 1.31-4.62, P=0.005), vascular emboli (HR=2.79; 95%CI 1.74-4.47, P<0.001) and stage T4 (HR=2.16; 95%CI 1.31-3.56, P=0.002). CONCLUSIONS Bowel obstruction, vascular emboli and stage T4 are independently associated with MSI CRC recurrence, suggesting that screening for vascular emboli in routine clinical practice may assist with adjuvant chemotherapy decision-making.
World Journal of Gastroenterology | 2011
Nicolas Williet; Olivier Dubreuil; Tarek Boussaha; Isabelle Trouilloud; Bruno Landi; Martin Housset; Muriel Botti; Philippe Rougier; Jacques Belghiti; Julien Taieb
This paper reports the first case of a patient with hepatocellular carcinoma with lymph node metastasis treated by sorafenib combined with gemcitabine plus oxaliplatin, with a partial response and normalization of α fetoprotein, which allowed curative surgery. The potential synergy between these three drugs needs to be confirmed, and is currently being investigated in a randomized phase II trial.
European Journal of Gastroenterology & Hepatology | 2012
Marine Camus; Isabelle Trouilloud; Ana L. Villacis; Luigi Mangialavori; Jean-Christophe Duchmann; Marianne Gaudric; Gilles Roseau; Benoit Terris; Emmanuel Mitry; Stanislas Chaussade; Frédéric Prat
Background Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) can be coupled with endoscopic retrograde cholangiopancreatography in the same setting when biliary and/or duodenal stenting are required. Aims Our aim was to examine the effectiveness of EUS-FNA combined with stenting during the same session in patients with pancreatic cancer. Methods Consecutive patients referred for EUS-FNA of a pancreatic mass with symptoms of biliary (±upper digestive) obstruction were included. Consecutive patients undergoing biliary and/or duodenal stenting without EUS-FNA during the same period were used as controls. Procedure-related complications were the primary outcome measure. Duration of the procedure, ability to achieve biliary/duodenal stenting, the yield of EUS-FNA, and clinical outcomes were evaluated. Results A total of 122 patients underwent combined EUS-FNA and stenting and 68 underwent stenting alone (control group). In the combined group, histological proof of cancer was obtained in 88.52% at first EUS-FNA and 95.08% after a second EUS-FNA. Biliary stent placement was successful in 97.5 and 98% in the combined and the control groups, respectively. There was no statistical difference between the groups for length of stay after endoscopy and for procedure-related mortality and morbidity within 30 days. The median time from endoscopy to chemotherapy in the combined group was 12 days. Conclusion Combined EUS-FNA and biliary and/or duodenal stenting is feasible in almost all patients with suspected pancreatic cancer, with no additional hazard and a high histological yield.
PLOS ONE | 2015
Amélie Anota; Guillaume Mouillet; Isabelle Trouilloud; Anne-Claire Dupont-Gossart; Pascal Artru; Thierry Lecomte; A. Zaanan; Mélanie Gauthier; Francine Fein; Olivier Dubreuil; Sophie Paget-Bailly; J. Taieb; Franck Bonnetain
Background A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using FOLFIRI.3 and gemcitabine alternately (Arm 2) compared to gemcitabine alone (Arm 1) in patients with metastatic non pre-treated pancreatic adenocarcinoma. The primary endpoint was the progression-free survival (PFS) rate at 6 months. It concludes that the sequential treatment strategy appears to be feasible and effective with a PFS rate of 43.5% in Arm 2 at 6 months (26.1% in Arm 1). This paper reports the results of the longitudinal analysis of the health-related quality of life (HRQoL) as a secondary endpoint of this study. Methods HRQoL was evaluated using the EORTC QLQ-C30 at baseline and every two months until the end of the study or death. HRQoL deterioration-free survival (QFS) was defined as the time from randomization to a first significant deterioration as compared to the baseline score with no further significant improvement, or death. A propensity score was estimated comparing characteristics of partial and complete responders. Analyses were repeated with inverse probability weighting method using the propensity score. Multivariate Cox regression analyses were performed to identify independent factors influencing QFS. Results 98 patients were included between 2007 and 2011. Adjusting on the propensity score, patients of Arm 2 presented a longer QFS of Global Health Status (Hazard Ratio: 0.52 [0.31-0.85]), emotional functioning (0.35 [0.21–0.59]) and pain (0.50 [0.31 – 0.81]) than those of Arm 1. Conclusion Patients of Arm 2 presented a better HRQoL with a longer QFS than those of Arm 1. Moreover, the propensity score method allows to take into account the missing data depending on patients’ characteristics. Trial registration information Eudract N° 2006-005703-34. (Name of the Trial: FIRGEM).
Clinics and Research in Hepatology and Gastroenterology | 2013
Bertrand Brieau; Hélène Roussel; Theofano Markoutsaki; Olivier Dubreuil; Isabelle Trouilloud; Bruno Landi; C. Lepere; Jean-Nicolas Vaillant; Anne Berger; P. Rougier; J. Taieb; A. Zaanan
The development of ovarian metastases from gastric cancer indicates a turning point of the disease progression and is usually associated with poor prognosis. Efficacy of modern chemotherapy protocols in ovarian metastases from gastric cancer is unknown. In this case series, we have evaluated the chemosensitivity of ovarian metastases from gastric cancer in eight consecutive patients treated in our institution between January 2000 and April 2012. Median age at gastric cancer diagnosis was 48.3 years and ovarian metastases were mainly metachronous (88%). Patients were treated with FOLFOX or FOLFIRI protocols in first-line and with EOX protocol in second-line chemotherapy. These protocols of chemotherapy used in first- and second-line treatment were able to control the disease in 33.3% for ovarian metastases compared to 66.7% for extraovarian metastases. Mean overall survival (OS) from ovarian metastases diagnosis was 14.2 months. The four patients treated by bilateral oophorectomy had a longer mean OS (16 months) than the four patients who did not experienced surgery (12.3 months). In conclusion, this case series suggests that ovarian metastases from gastric cancer are less sensitive than extraovarian metastases to modern protocol of chemotherapy. To confirm these observations, a large retrospective study is ongoing.
Hépato-Gastro & Oncologie Digestive | 2012
Aziz Zaanan; Olivier Dubreuil; Isabelle Trouilloud; Pierre Laurent-Puig; Julien Taieb
Le phenotype microsatellites instables (MSI) est trouve dans environ 15 % des cancers colorectaux et peut etre d’origine sporadique ou hereditaire. Plusieurs etudes ont montre que les patients avec une tumeur MSI avaient un meilleur pronostic que les patients avec une tumeur a microsatellites stables. Les donnees cliniques les plus recentes indiquent que les patients avec une tumeur MSI de forme hereditaire traites par 5-fluorouracile (5-FU) en situation adjuvante pourraient avoir un gain de survie, contrairement aux formes sporadiques qui n’en beneficieraient pas. En revanche, il n’existe que peu de donnees concernant le traitement adjuvant par FOLFOX. Certaines donnees preliminaires issues d’etudes retrospectives suggerent que l’adjonction d’oxaliplatine au 5-FU pourrait apporter un gain de survie pour les patients MSI de stade III. Toutefois, ces resultats devront etre confirmes par l’analyse en cours des echantillons tumoraux provenant des essais randomises anterieurement publies comparant le 5-FU au FOLFOX (etudes MOSAIC et NSABP-C07).
Annals of Surgical Oncology | 2015
Daniel Pietrasz; Lysiane Marthey; Mathilde Wagner; Jean-Frédéric Blanc; Christophe Laurent; Olivier Turrini; Jean Luc Raoul; Eric Terrebonne; Olivia Hentic; Isabelle Trouilloud; Romain Coriat; Nicolas Regenet; Pasquale F. Innominato; Julien Taieb; Antonio Sa Cunha; Jean-Baptiste Bachet
BMC Cancer | 2014
A. Zaanan; Isabelle Trouilloud; Theofano Markoutsaki; Mélanie Gauthier; Anne-Claire Dupont-Gossart; Thierry Lecomte; Thomas Aparicio; Pascal Artru; Anne Thirot-Bidault; Fanny Joubert; Daniella Fanica; J. Taieb